These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 1621284)

  • 1. [Current status and perspectives for genetic consultation and prophylactic medical examination of risk groups with malignant neoplasms of the female reproductive system and breast].
    Akulenko LV; Gar'kavtseva RF; Zhordania KI; Samgina AA
    Tsitol Genet; 1992; 26(1):38-42. PubMed ID: 1621284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Tumor risk consultation for predisposed women from high risk cancer families].
    Beckmann MW; Niederacher D; Bodden-Heidrich R; Goecke TO; Kuschel B; Achnoula M; Aba F; Schnürch HG; Bender HG
    Praxis (Bern 1994); 1998 Apr; 87(15):511-5. PubMed ID: 9608246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast & ovarian cancer. Issues in risk assessment.
    Caro SW
    Adv Nurse Pract; 1999 Aug; 7(8):26-32; quiz 33-4. PubMed ID: 10745719
    [No Abstract]   [Full Text] [Related]  

  • 4. Genetics and the multidisciplinary breast center.
    Peters JA; Rubinstein WS
    Surg Oncol Clin N Am; 2000 Apr; 9(2):367-96. PubMed ID: 10757850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Analysis of the genetic predisposition to cancer in families of patients with multiple primary malignant neoplasms].
    Gar'kavtseva RF; Kazubskaia TP; Sel'chuk VIu
    Tsitol Genet; 1992; 26(2):32-6. PubMed ID: 1615556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical and molecular diagnosis of inherited breast-ovarian cancer].
    Chompret A
    J Gynecol Obstet Biol Reprod (Paris); 2003 Apr; 32(2):101-19. PubMed ID: 12717301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Recommendations for treatment of individuals at risk for hereditary breast and ovarian carcinoma].
    Radulović S; Branković-Magić M; Janković R; Ristanović M
    Srp Arh Celok Lek; 2003; 131(7-8):345-50. PubMed ID: 14692152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Recommendations for the management of women with an increased genetic risk of gynaecological cancer].
    Verheijen RH; Boonstra H; Menko FH; de Graaff J; Vasen HF; Kenter GG
    Ned Tijdschr Geneeskd; 2002 Dec; 146(50):2414-8. PubMed ID: 12518519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical implications of genetic testing for inherited breast and ovarian cancer risk.
    Calzone KA
    Nurs Spectr (Wash D C); 1998 Nov; 8(23):12-4. PubMed ID: 10542772
    [No Abstract]   [Full Text] [Related]  

  • 10. Simultaneous interdisciplinary counseling in German breast/ovarian cancer families: first experiences with patient perceptions, surveillance behavior and acceptance of genetic testing.
    Hofferbert S; Worringen U; Backe J; Rückert EM; White K; Faller H; Grimm T; Caffier H; Chang-Claude J; Weber BH
    Genet Couns; 2000; 11(2):127-46. PubMed ID: 10893664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Counselling, genetic testing and prevention in women with hereditary breast- and ovarian cancer. Interdisciplinary recommendations of the consortium "Hereditary Breast- and Ovarian Cancer" of the German Cancer AiD].
    Schmutzler R; Schlegelberger B; Meindl A; Gerber WD; Kiechle M;
    Zentralbl Gynakol; 2003 Dec; 125(12):494-506. PubMed ID: 14755360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychosocial issues following a positive result of genetic testing for BRCA1 and BRCA2 mutations: findings from a focus group and a needs-assessment survey.
    Di Prospero LS; Seminsky M; Honeyford J; Doan B; Franssen E; Meschino W; Chart P; Warner E
    CMAJ; 2001 Apr; 164(7):1005-9. PubMed ID: 11314429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic counselling and testing for susceptibility to breast, ovarian and colon cancer: where are we today?
    Cole DE; Gallinger S; McCready DR; Rosen B; Engel J; Malkin D
    CMAJ; 1996 Jan; 154(2):149-55. PubMed ID: 8548703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receiving inconclusive genetic test results: an interpretive description of the BRCA1/2 experience.
    Maheu C; Thorne S
    Res Nurs Health; 2008 Dec; 31(6):553-62. PubMed ID: 18449940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticipated uptake and impact of genetic testing in hereditary breast and ovarian cancer families.
    Struewing JP; Lerman C; Kase RG; Giambarresi TR; Tucker MA
    Cancer Epidemiol Biomarkers Prev; 1995 Mar; 4(2):169-73. PubMed ID: 7742725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic risk assessment for breast and ovarian cancer.
    O'Rourke Tiffen J; Pfeifer K; Fishman DA
    Adv Nurse Pract; 2003 Oct; 11(10):40-8. PubMed ID: 14601495
    [No Abstract]   [Full Text] [Related]  

  • 17. A current perspective on genetic testing for breast and ovarian cancer: the oral contraceptive decision.
    Friedenson B
    MedGenMed; 2001 Nov; 3(6):2. PubMed ID: 11965197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pros and cons of genetic testing for breast and ovarian cancer risk.
    Frank TS; Braverman AM
    Int J Fertil Womens Med; 1999; 44(3):139-45. PubMed ID: 10435912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic counseling, testing, and screening for breast and ovarian cancer: practical and social considerations.
    Khabele D; Runowicz CD
    Curr Womens Health Rep; 2002 Jun; 2(3):163-9. PubMed ID: 12099190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Experiences from a clinic for patients with hereditary cancer. Diagnosis of genetic carriers may prevent cancer].
    Lindblom A; Iselius L
    Lakartidningen; 1995 May; 92(18):1915-8. PubMed ID: 7746044
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.